Bhupendar Tayal
Sourced from institutional research profiles (UAMS TRI or ARA).
Assistant Professor
Faculty Researcher
COM | Internal Med Cardiology
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Bhupendar Tayal studies cardiovascular function and risk factors. His work includes research on blood pressure and hypertension, as well as heart failure treatment and management. Tayal also investigates mechanical circulatory support devices and cardiac arrest and resuscitation.
Metrics
- h-index: 18
- Publications: 128
- Citations: 1,266
Selected Publications
-
AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)
-
Prognostic importance of septal deformation patterns and lateral wall function in patients with heart failure and left bundle branch block receiving cardiac resynchronization therapy (2026)
-
Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram (2026)
-
26-A-21124-ACC PREDICTORS OF MYOCARDIAL RECOVERY IN HEART FAILURE WITH REDUCED EJECTION FRACTION (2026)
-
26-A-18480-ACC INCIDENCE AND PREDICTORS OF HIGH-GRADE ATRIOVENTRICULAR BLOCK AFTER TRANSCATHETER TRICUSPID VALVE REPLACEMENT: A REAL-WORLD ANALYSIS (2026)
-
26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS (2026)
-
26-A-16106-ACC SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) IN PULMONARY HYPERTENSION (PH): A SYSTEMATIC REVIEW (2026)
-
26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS (2026)
-
1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia (2026)
-
Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study (2025)
-
Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve (2025)
Collaboration Network
Top Collaborators
- Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve
- Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve
- Diagnosis and Diagnostic Challenges of Secondary Mitral Regurgitation in the Era of Transcatheter Edge-to-Edge Repair of the Mitral Valve
- Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study
- Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study
- Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study
- Abstract 4365455: Outcomes of Transcatheter Edge-to-Edge Repair of the Mitral Valve in Cirrhosis: A TriNetX Based Global Study
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
- 1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia
Similar Researchers
Based on overlapping research topics